Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1085)	7/28/2006 12:05:00 PM
From: tuck	Read Replies (1) \| Respond to of 3661

>>You'll remember from discussions subsequent to Large Scale visit, that anti-id is an old tale. The antigen is there. But B cells are DESIGNED to make that antigen hypervariable. Past attempts (largely at Idec, back before they were saved from bankruptcy brink by Genentech) have shown that a successful immunization doesn't lead to prolonged survival.<< That discussion pops into my head every time GTOP comes across my radar, and it kept me away from GTOP, though I never shorted it. So thanks are due to you, sir! Oh, and I think I still owe you a couple of pizzas and a cup of coffee. Cheers, Tuck